AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
MacroGenics, Inc.
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001S9C8R7
2.25▼ 1.38 (-38.02%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
3.63
Day's Range
2.13 – 3.57
52-Week Range
1.29 – 5.08
Volume
4.0M
Avg Volume
652.1K
Share Statistics
Shares Outstanding
Employees
293
Exchange
XNAS
Listed
2013-10-10
Share count as of August 8, 2026

MacroGenics, Inc. (MGNX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about MacroGenics, Inc. (MGNX)
What is MacroGenics, Inc.'s Market Cap?
MacroGenics, Inc.'s Market Cap is $143.3M, based on as-reported figures from SEC (XBRL) filings.
What is MacroGenics, Inc.'s Enterprise Value?
MacroGenics, Inc.'s Enterprise Value is $29.4M, based on as-reported figures from SEC (XBRL) filings.
What is MacroGenics, Inc.'s Price / Sales?
MacroGenics, Inc.'s Price / Sales is 0.8×, based on as-reported figures from SEC (XBRL) filings.
What is MacroGenics, Inc.'s EV / Revenue?
MacroGenics, Inc.'s EV / Revenue is 0.2×, based on as-reported figures from SEC (XBRL) filings.
What is MacroGenics, Inc.'s EV / EBITDA?
MacroGenics, Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is MacroGenics, Inc.'s Revenue (TTM)?
MacroGenics, Inc.'s Revenue (TTM) is $175.1M, based on as-reported figures from SEC (XBRL) filings.
What is MacroGenics, Inc.'s Net Income (TTM)?
MacroGenics, Inc.'s Net Income (TTM) is -$14.6M, based on as-reported figures from SEC (XBRL) filings.
What is MacroGenics, Inc.'s EBITDA?
MacroGenics, Inc.'s EBITDA is -$32.2M, based on as-reported figures from SEC (XBRL) filings.
What is MacroGenics, Inc.'s Diluted EPS (TTM)?
MacroGenics, Inc.'s Diluted EPS (TTM) is -0.23, based on as-reported figures from SEC (XBRL) filings.
What is MacroGenics, Inc.'s EBITDA Margin?
MacroGenics, Inc.'s EBITDA Margin is -18.4%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · MGNXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues:
Total revenues
YoY growth+378.0%+57.5%+113.0%-34.2%
Costs and expenses:
Research and development
General and administrative
Total costs and expenses
% of revenue142.2%261.0%129.3%74.4%
Loss from operations
% of revenue-42.2%-161.0%-29.3%25.6%
Loss on extinguishment of royalty monetization liability———
Interest and other income
Interest and other expense
Loss before income taxes—
Income tax provision—
Net loss from continuing operations———
Net income (loss)
% of revenue59.4%-177.0%-34.3%23.1%
Net income (loss) per share - basic (in usd per share)
Net income (loss) per share - diluted (in usd per share)